SS-31 is marketed online as an "anti-ageing" peptide, and the pitch is usually some version of fix the mitochondria, slow the clock. The compound itself — elamipretide, a four-amino-acid, cardiolipin-binding tetrapeptide — now has a genuine regulatory milestone behind it, so the temptation to extrapolate is stronger than ever. But the two studies that directly tested the ageing claim landed in an awkward place: function improved, and the molecular ageing clocks didn't budge. That gap is the most useful thing in the current SS-31 research literature, and it's rarely mentioned in the marketing. Here's what the data actually show, and where SS-31 in Australia sits from a regulatory point of view.

What is SS-31 (elamipretide)?

SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH₂) is a synthetic tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin — the phospholipid that organises electron transport chain supercomplexes and holds cristae curvature. The proposed consequence is more efficient oxidative phosphorylation and less electron leak, rather than "more mitochondria". It's delivered by injection; there is no meaningful oral route.

That mechanism is the reason ageing researchers got interested. Mitochondrial capacity falls with age in skeletal muscle and heart, so a drug that restores membrane organisation is a plausible geroprotector on paper. Plausible is not proven. You can read the full profile at /peptides/ss-31.

The human ageing trial: one dose, one endpoint, one caveat

The most-cited human ageing data is a randomised, double-blind, placebo-controlled trial in 39 healthy adults aged 60–85, selected for poor baseline mitochondrial function, published in PLOS One in 2021. Participants received a single two-hour infusion of elamipretide or placebo, with magnetic resonance and optical spectroscopy used to measure mitochondrial capacity (ATPmax) and coupling.

Three findings matter, and most summaries only quote the first:

  • ATPmax rose relative to placebo immediately after the infusion (%ΔATPmax p = 0.045; ΔATPmax p = 0.055 — note the second of those does not clear the conventional 0.05 threshold).
  • Fatigue resistance did not improve. There was no significant treatment effect on fatigue resistance in the muscle studied.
  • The effect was reversible. Capacity returned toward baseline, which the authors framed as rapid and transient pharmacology, not remodelling.

So the honest one-line reading is: a single dose of SS-31 acutely raised a measure of mitochondrial energy production in older muscle, without a matching change in how that muscle performed. It is a small, single-dose study. It has not been replicated as a chronic-dosing functional trial in healthy older adults.

The clock test: function improved, epigenetic age didn't

The more interesting experiment ran in mice. A 2025 Aging Cell paper from Mitchell and colleagues gave aged mice chronic elamipretide and then measured both function and molecular age.

On function, the results were positive: improvements in cardiac systolic and diastolic measures including global longitudinal strain and ejection fraction, reduced frailty accumulation, and attenuation of the age-related decline in muscle force — the muscle effect being clearest in female mice.

On biological age, the results were negative. The authors did not detect statistically significant changes in DNA methylation clocks or transcriptomic age in most treated groups. Pathway analysis did show longevity-flavoured shifts — fatty acid metabolism, mitochondrial translation and oxidative phosphorylation genes up, inflammation down — but that's a direction of travel, not a clock reading.

The title of that paper is essentially the whole argument: improved cardiac and skeletal muscle function during ageing without detectable changes in tissue epigenetic or transcriptomic age. If your mental model of SS-31 is "it turns back your biological age", this is the study designed to test that, in animals, and it says no. If your model is "it may help tissue work better while the underlying ageing programme runs on", the data are more supportive — in mice.

Why the distinction isn't pedantic

Epigenetic clocks are imperfect surrogates, and a drug can improve healthspan without moving them. But the ageing-clock claim is exactly what's used to sell peptides, and it is now the specific claim with a null result attached. Preclinical function data in aged mice also do not transfer automatically to humans — the single-dose human trial above is the only in-human ageing-adjacent evidence, and its functional endpoint was negative.

Is SS-31 legal in Australia, and what's the regulatory status?

The regulatory picture is narrow and worth stating precisely.

Elamipretide received FDA accelerated approval on 19 September 2025 as Forzinity, for Barth syndrome in patients weighing at least 30 kg — after an earlier complete response letter. It is the first FDA-approved therapy directly targeting mitochondria. The approval rested on an intermediate endpoint, improvement in knee extensor muscle strength, and continued approval is conditional on a confirmatory trial. Mighty Therapeutics (formerly Stealth BioTherapeutics, renamed June 2026) dosed the first patient in the Phase 4 confirmatory 4TAZPower study on 8 July 2026, with primary completion not expected until September 2029.

It's equally important that the Phase 3 programme in primary mitochondrial myopathy — a much larger and more general indication — missed both primary endpoints. One ultra-rare approval on a surrogate endpoint plus one failed Phase 3 in a broader population is not a foundation for general wellness use.

In Australia: elamipretide is not on the ARTG. There is no TGA-approved SS-31 product, for Barth syndrome or anything else. Unapproved therapeutic goods can only be lawfully supplied to a patient through pathways like the Special Access Scheme or an Authorised Prescriber, at a clinician's initiative. Material sold online labelled "research use only" is not an alternative legal route to personal use, and vials of that kind carry no assurance of identity, purity or sterility. On the known safety side, the US label lists injection site reactions — erythema, pain, induration, pruritus, bruising, urticaria — as the most common adverse reactions, and carries a warning about benzyl alcohol in neonates.

Australians following the mitochondrial space should treat SS-31 as an overseas orphan drug with one narrow approval and an open confirmatory obligation, not an available therapy. We track approvals and trial readouts for this and other compounds across /peptides — join the free updates list if you want the next Forzinity or 4TAZPower milestone as it lands.

What would actually change the picture

Three things, none of which exist yet:

  1. A chronic-dosing randomised trial in older adults with a hard functional primary endpoint — walking speed, strength, fatigue resistance — not just ATPmax.
  2. Replication of the mouse healthspan findings in an independent lab, ideally in both sexes given the female-skewed muscle effect.
  3. The 4TAZPower confirmatory readout, which will determine whether the one existing approval stands.

Until then, SS-31's human evidence base is: one approved ultra-rare indication on a surrogate endpoint, one failed Phase 3, and one small single-dose ageing trial whose functional endpoint was null.

FAQ

What is SS-31 (elamipretide)?

SS-31 is a synthetic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, with the aim of improving electron transport chain efficiency. It is given by injection and is approved in the US only as Forzinity for Barth syndrome.

Does SS-31 reverse biological age?

There's no evidence it does. A 2025 Aging Cell study in aged mice found elamipretide improved cardiac and muscle function but produced no detectable change in DNA methylation or transcriptomic age — and that's animal data, not human.

Is SS-31 legal in Australia?

Elamipretide is not on the ARTG and has no TGA approval, so there is no legally marketed SS-31 product in Australia. Unapproved goods can only reach patients via clinician-initiated pathways such as the Special Access Scheme or Authorised Prescriber.

Has SS-31 been shown to improve strength or fatigue in older adults?

Not yet. The one randomised trial in 39 adults aged 60–85 found a single infusion raised mitochondrial ATP production acutely, but showed no significant improvement in fatigue resistance, and the effect was reversible.

Sources

This article is independent information, not medical advice. Elamipretide holds US accelerated approval for Barth syndrome only, is not on the ARTG, and is investigational for every other use discussed here — speak to a qualified Australian health professional about your own situation.